Login to Your Account

Other news to note

Wednesday, February 19, 2014

Sorrento Therapeutics Inc., of San Diego, obtained exclusive rights to Cynviloq (Genexol-PM) in Australia, Canada and Mexico from Samyang Biopharmaceuticals, of South Korea. Sorrento already has exclusive rights from Samyang in the U.S. and the 27 European Union countries. Cynviloq is a next-generation branded paclitaxel formulation to treat metastatic breast cancer, non-small-cell lung cancer, pancreatic cancer, and other solid tumors.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription